Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523085-24-00

Enrollment

Registered

2026-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Tract Cancer

Brief summary

Overall survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy

Detailed description

Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy

Interventions

DRUGMYCOPHENOLATE MOFETIL

DRUGINFLIXIMAB

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion

DRUGRilvegostomig

DRUGGEMCITABINE

DRUGCISPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy	—

Secondary

Measure	Time frame
Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 24, 2026